Type 2 diabetes a growing problem in Australia

Original article by Roy Morgan Research
Market Research Update – Page: Online : 15-Oct-15

A Roy Morgan Single Source survey has found that the number of Australians aged 18+ diagnosed with some form of diabetes has increased from 915,000 to more than 1.2 million since 2007. This growth was driven primarily by a rise in Type 2 diabetes, which accounts for just over 90 per cent of Australians 18+ diagnosed with diabetes. The survey, which was carried out in the year to June 2015, also shows that people with Type 2 diabetes are twice as likely as the average Australian to be classified as obese (54 per cent vs 26 per cent), and markedly less likely to participate in regular or occasional sport/exercise (34 per cent vs 47 per cent). Meanwhile, 83 per cent of Type 2 diabetics are aged 50 years or older, while more than half of people with the condition are from the less affluent E and FG quintiles.

CORPORATES
ROY MORGAN RESEARCH LIMITED

Diabetes trial success

Original article by Tim Binsted
The Australian Financial Review – Page: 22 : 9-Jun-15

Listed biotechnology group Mesoblast has reported encouraging results from the phase two trial of a treatment for diabetic nephropathy. CEO Silviu Itescu says nearly two million people had the diabetes-related kidney disease in 2013. The clinical trial found that the stem cell-based treatment showed that participants had improved kidney function and experienced no adverse side-effects.

CORPORATES
MESOBLAST LIMITED – ASX MSB, AMERICAN DIABETES ASSOCIATION, CELGENE INCORPORATED, SIRTEX MEDICAL LIMITED – ASX SRX

Perth toddler first person to get artificial pancreas

Original article by Aleisha Orr
The Age – Page: 10 : 22-Jan-15

A team at Princess Margaret Hospital for Children in Perth has fitted a newly developed medical device that functions as an artificial pancreas to a four-year-old boy suffering from type-1 diabetes. The battery-powered pump supplies insulin in doses according to automated readings of glucose levels, in order to prevent hypoglycaemic attacks. The product is already freely available to diabetes patients, including adults, but the cost is still high at $A10,000

CORPORATES
PRINCESS MARGARET HOSPITAL